Results 111 to 120 of about 182,433 (270)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

, 2019
Caixia Zheng,1,* Honghong Yan,2,* Jianyong Zeng,1,* Shaohang Cai,2,3 Xiaolu Wu11Department of Infectious Diseases, First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, People’s Republic of China; 2Intensive Care Unit, Sun Yat ...
Cai S, Zheng C, Zeng J, Yan H, Wu X
core  

Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report

, 2009
Interstitial pneumonitis is a rare but potentially fatal side effect occurring from 2 weeks to 16 weeks after the initiation of treatment with pegylated interferon alpha and ribavirin for chronic hepatitis C.Herein, we present a 68-year-old man with ...
ÖZEN ALAHDAB, YEŞİM
core   +1 more source

Long-term pegylated interferon-α and its potential in the treatment of melanoma

, 2009
Reinhard Dummer, Joanna ManganaDepartment of Dermatology, University Hospital, Zürich, SwitzerlandAbstract: Conventional interferons including interferon-α (IFN-α) are cytokines used for years in the treatment of solid tumors
Reinhard Dummer, Joanna Mangana
core  

Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C.

, 2004
There is no standard approved treatment for acute hepatitis C and the combination of pegylated interferon-alpha and ribavirin, currently recognized as the standard of care for chronic hepatitis C, has not been evaluated for acute hepatitis C.
Devière, Jacques, Marcellin, P, Golstein, Philippe, Delforge, Marie-Luce   +3 more
core   +1 more source

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

, 2022
Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis.
Chan-Yen Tsai, Qin, Albert, Huang, Yi-Wen, Yi-Wen Huang, Chen, Pei-Jer, Pei-Jer Chen, Albert Qin, Tsai, Chan-Yen   +7 more
core   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Colonia Uceda Renteria, Annapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection

Kaohsiung Journal of Medical Sciences, 2017
Posttransplant hepatitis C virus (HCV) recurrence is universal in chronic hepatitis C recipients. Antiviral therapy is suggested after liver transplant to halt disease progression.
Ta-Ya Lin, Ming-Lun Yeh, Ching-I Huang, Yao-Li Chen, Chia-Yen Dai, Jee-Fu Huang, Zu-Yau Lin, Shinn-Cherng Chen, Chung-Feng Huang, Ming-Lung Yu, Wan-Long Chuang   +10 more
doaj   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility

, 2008
Cost-utility, EQ-5D, SF-6D, Health utilities,
Marina Grishchenko, Richard Grieve, Grieve, Richard, Cairns, John, Grishchenko, Marina, John Cairns   +5 more
core   +1 more source

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A

, 2023
Hairy cell leukemia (HCL) treatment in elderly, frail subjects is still unsatisfactory, and interferons, old-fashioned therapies, can be effectively used in this subset of patients. Here, to the best of our knowledge, we report for the first time an old,
De Novellis D., Picone F., Ciccone V., De Vita A., Giudice V., Erra P., Selleri C., Serio B.   +7 more
core   +1 more source